文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

单次HDR近距离放疗联合SBRT治疗中高危前列腺癌:前瞻性II期研究结果

Single-fraction HDR brachytherapy combined with SBRT for intermediate and high-risk prostate cancer: Oncologic and patient-reported outcomes from a prospective phase II study.
PubMed 文献 · Radiother Oncol · 2026-06-09

中位随访48个月,4年bRFS和MFS均为91%,无3级GI毒性,仅2例(2.6%)出现晚期3级GU毒性,生活质量在6个月内恢复至基线。

要点

  • 单次HDR近距离放疗联合SBRT方案可行,4年bRFS和MFS均为91%。
  • 无3级GI毒性,晚期3级GU毒性仅2.6%,急性2级GU毒性11.8%。
  • 泌尿和肠道生活质量在1个月时短暂下降,6个月恢复至基线。

核心结论

  • 单次HDR近距离放疗联合SBRT实现了高中危前列腺癌的高生化控制,毒性有限且保留生活质量,是一种高效的剂量递增策略。

研究设计与样本

  • 治疗方案为MRI-TRUS融合HDR近距离放疗(15 Gy单次)后行前列腺SBRT(25 Gy分5次),根据风险组给予雄激素剥夺治疗。
  • 主要终点为患者报告生活质量(EPIC-26、EORTC QLQ-PR25),次要终点包括急性和晚期GU/GI毒性(CTCAE v5)、PSA反应、bRFS、MFS和OS。

主要发现

  • 中位随访48个月,未观察到急性和晚期3级GI毒性。
  • 2例(2.6%)出现晚期3级GU毒性;急性和晚期2级GU毒性发生率分别为11.8%和28.9%。
  • 泌尿和肠道生活质量在1个月时出现短暂且非显著下降,6个月恢复至基线。
  • 中位PSA谷值为0.04 ng/mL,4年时中位PSA为0.06 ng/mL。
  • 4年bRFS和MFS均为91%(95%CI 84-98%)。

关键数值与推荐

  • HDR近距离放疗剂量为15 Gy单次,SBRT剂量为25 Gy分5次。
  • 4年bRFS和MFS均为91%(95%CI 84-98%)。
  • 晚期3级GU毒性发生率为2.6%,急性和晚期2级GU毒性发生率分别为11.8%和28.9%。
  • 中位PSA谷值为0.04 ng/mL,4年时中位PSA为0.06 ng/mL。

临床怎么用

  • 对于中高危前列腺癌,可考虑单次HDR近距离放疗联合前列腺SBRT作为高效剂量递增方案。
  • 治疗前应告知患者泌尿毒性风险及生活质量短暂下降后恢复的可能性。
  • 需关注晚期GU毒性,尤其是2级及以上事件的发生。

局限性

  • 未设置对照组,无法直接比较其他剂量递增策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Brachytherapy boost is an established dose-escalation strategy in intermediate- and high-risk prostate cancer, while stereotactic body radiotherapy (SBRT) offers treatment efficiency with favourable radiobiology. We report mature results of a prospective phase II trial combining single-fraction high-dose-rate (HDR) brachytherapy with prostate-only SBRT. MATERIALS AND METHODS: Seventy-six patients with intermediate- or high-risk prostate cancer were enrolled between 2019 and 2021. Treatment consisted of MRI-TRUS fusion HDR brachytherapy (15 Gy, single fraction) followed by SBRT (25 Gy in 5 fractions). Androgen deprivation therapy was prescribed according to risk group. The primary endpoint was patient-reported quality of life (EPIC-26, EORTC QLQ-PR25). Secondary endpoints included acute and late genitourinary (GU) and gastrointestinal (GI) toxicity (CTCAE v5), PSA response, biochemical relapse-free survival (bRFS), metastasis-free survival (MFS), and overall survival (OS). RESULTS: With a median follow-up of 48 months, no acute or late grade 3 GI toxicity was observed. Two patients (2.6 %) developed late grade 3 GU toxicity. Acute and late grade 2 GU toxicity occurred in 11.8 % and 28.9 % of patients, respectively. Urinary and bowel quality of life showed a transient and non-significant decline at one month, returning to baseline by six months. The median PSA nadir was 0.04 ng/mL. The 4-year bRFS and MFS were both 91 % (95 % CI 84-98 %). The median PSA at 4 years was 0.06 ng/mL. CONCLUSIONS: Single-fraction HDR brachytherapy combined with SBRT achieved high biochemical control with limited toxicity and preserved quality of life, representing an efficient dose-escalation strategy for intermediate- and high-risk prostate cancer.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Büchser D, Zaragoza L, Valverde I, et al. Single-fraction HDR brachytherapy combined with SBRT for intermediate and high-risk prostate cancer: Oncologic and patient-reported outcomes from a prospective phase II study. Radiother Oncol. 2026. PMID: 42264093. doi:10.1016/j.radonc.2026.111639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。